EE: Ethinyl estradiol; LNG: Levonorgestrel; OC: Oral contraceptive; RR: Relative risk; VTE: Venous thromboembolism. Transdermal contraceptive patches provide a more convenient delivery system for ...

PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration ...

Blood clot risk elevated with contraceptive patches, vaginal rings Women who use the combined contraceptive transdermal patch or vaginal ring are at significantly higher risk for venous thrombosis, ...

Agile Says Growing Demand For Twirla (levonorgestrel and ethinyl estradiol ) transdermal system Is Helping It Stay On Track to Hit $25-$30 Million Net Revenue PRINCETON, NJ / ACCESSWIRE / July 3, 2023 ...

(MENAFN- Market Press Release) November 25, 2025 2:59 am - The Transdermal Contraceptive Patches Market, valued at USD 800 million in 2025, is set to grow at a 6% CAGR through 2032. Global Transdermal ...

The U.S. Food and Drug Administration approved additional changes to the Ortho Evra Contraceptive Transdermal (Skin) Patch label to include the results of a new epidemiology study that found that ...

The patch supplies norelgestromin and ethinyl estradiol to the bloodstream through the skin. Has any evidence of genital swelling been documented with the use of the patch when placed inappropriately?

Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the Company), a ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...